Glaucoma – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of glaucoma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of glaucoma for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s glaucoma forecast will answer the following question:

• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of glaucoma over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts seven glaucoma patient populations, as follows:

• Total glaucoma prevalent cases.
• Diagnosed glaucoma prevalent cases.
• Undiagnosed glaucoma prevalent cases.
• Total primary glaucoma prevalent cases.
• Total primary open-angle glaucoma prevalent cases.
• Total primary angle closure glaucoma prevalent cases.
• Total secondary glaucoma prevalent cases.

Note: Coverage may vary by country.